Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

November 7, 2013 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode

The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

400

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Tuscaloosa, Alabama, United States
        • Local Institution
    • Arkansas
      • Little Rock, Arkansas, United States
        • Local Institution
    • California
      • San Diego, California, United States
        • Local Institution
      • Sherman Oaks, California, United States
        • Local Institution
    • Connecticut
      • Norwich, Connecticut, United States
        • Local Institution
      • West Haven, Connecticut, United States
        • Local Institution
    • Florida
      • Jacksonville, Florida, United States
        • Local Institution
      • Maitland, Florida, United States
        • Local Institution
      • Orlando, Florida, United States
        • Local Institution
    • Hawaii
      • Honolulu, Hawaii, United States
        • Local Insstitution
    • Illinois
      • Chicago, Illinois, United States
        • Local Institution
    • Louisiana
      • Lake Charles, Louisiana, United States
        • Local Institution
    • Maryland
      • Rockville, Maryland, United States
        • Local Institution
    • North Carolina
      • Durham, North Carolina, United States
        • Local Institution
      • Raleigh, North Carolina, United States
        • Local Institution
    • Ohio
      • Beachwood, Ohio, United States
        • Local Institution
      • Dayton, Ohio, United States
        • Local Institution
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
        • Local Institution
    • Oregon
      • Portland, Oregon, United States
        • Local Institution
    • Pennsylvania
      • Media, Pennsylvania, United States
        • Local Institution
    • Tennessee
      • Memphis, Tennessee, United States
        • Local Institution
    • Texas
      • Austin, Texas, United States
        • Local Institution
      • Dallas, Texas, United States
        • Local Institution
      • Houston, Texas, United States
        • Local Institution
      • Lake Jackson, Texas, United States
        • Local Institution
      • Wichita Falls, Texas, United States
        • Local Institution
    • Virginia
      • Arlington, Virginia, United States
        • Local Institution
    • Washington
      • Bellevue, Washington, United States
        • Local Institution

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • ages 18-65
  • Men and women, who have experienced a prior manic episode that required hospitalization, and now meet criteria for a major depressive episode.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: A1
Drug: Aripiprazole
Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
Other Names:
  • Abilify
Placebo Comparator: A2
Drug: Placebo
Tablets, Oral, 0 mg, Once daily, 8 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Change on a depression rating scale at endpoint

Secondary Outcome Measures

Outcome Measure
Response rate and Clinical Global Impression scale at endpoint

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

Otsuka America Pharmaceutical

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2004

Primary Completion (Actual)

October 1, 2006

Study Completion (Actual)

October 1, 2006

Study Registration Dates

First Submitted

March 26, 2004

First Submitted That Met QC Criteria

March 29, 2004

First Posted (Estimate)

March 30, 2004

Study Record Updates

Last Update Posted (Estimate)

November 11, 2013

Last Update Submitted That Met QC Criteria

November 7, 2013

Last Verified

June 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CN138-096

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bipolar Disorder

Clinical Trials on Aripiprazole

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe